Volume : 09, Issue : 11, November – 2022
Title:
32.AN OVERVIEW PROPER PHARMACOLOGICAL TREATMENT OF IMPETIGO
Authors :
Ola Hisham Ojaimi, Haifa khalid Aljuhani, Azzah Saleh Shabaan, Rawan Sami Alharbi, Mariyam Mohammed Qaed, Reham Ahmad Alemam, Manar Mohammad Allihaibi, Amwaj Faisal Ageeli, Nada Adel Bogis, Ghaida Siraj Mubarak
Abstract :
Impetigo is a highly contagious illness of the superficial epidermis that typically affects children between the ages of two and five, but can affect anybody. Currently affects around 162 million children worldwide. Lack of agreement on the most effective treatment strategy for impetigo and rising antibiotic resistance continue to motivate research into novel and alternative treatments. We combed PubMed, MEDLINE via EBSCOhost, CINAHL via EBSCOhost, Web of Science, and Embase via Scopus for studies published by February 29, 2022. There is no conventional treatment for impetigo, and there are numerous potential choices. Mupirocin and fusidic acid are efficient topical antibiotics that may be superior to oral antibiotics. Patients with significant illness should be considered for oral antibiotic therapy
Cite This Article:
Please cite this article in press Ola Hisham Ojaimi et al, An Overview Proper Pharmacological Treatment Of Impetigo.,Indo Am. J. P. Sci, 2022; 09(11).
Number of Downloads : 10
References:
2. Thomas J, Christenson J, Walker E, Baby K, Peterson G. Scabies-An ancient itch that is still rampant today. J Clin Pharm Ther. 2017;42:793.
3. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90:229–235.
4. Bowen AC, Mahé A, Hay RJ, et al. The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PloS one. 2015;10.
5. Aung PTZ, Cuningham W, Hwang K, et al. Scabies and risk of skin sores in remote Australian Aboriginal communities: A self-controlled case series study. PLoS Negl Trop Dis. 2018;12.
6. Pereira LB. Impetigo – review. An Bras Dermatol. 2014;89:293–299.
7. Bowen A, May P, Carapetis J, Tong S, Andrews R, Currie B. National Healthy Skin Guideline for the Prevention, Treatment and Public Health Control of Impetigo, Scabies, Crusted Scabies and Tinea for Indigenous Populations and Communities in Australia. 1st edition; 2018.
8. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10–e52.
9. Bowen AC, Tong SY, Andrews RM, et al. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. Lancet. 2014;384:2132–2140.
10. Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. The Cochrane Catabase Syst Rev. 2012;1.
11. Geria AN, Schwartz RA. Impetigo update: new challenges in the era of methicillin resistance. Cutis. 2010;85:65–70.
12. Antonov NK, Garzon MC, Morel KD, Whittier S, Planet PJ, Lauren CT. High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population. Antimicrob Agents Chemother. 2015;59:3350–3356.
13. Ilyas M, Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr Nephrol. 2008;23(7):1101-1106.
14. Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol. 2010;9(10):1198-1204.
15. Stevens DL, Bisno AL, Chambers HF, et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published corrections appear in Clin Infect Dis. 2006;42(8):1219 and Clin Infect Dis. 2005;41(12):1830]. Clin Infect Dis. 2005;41(10):1373-1406.
16. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334(4):240-245.
17. Feaster T, Singer JI. Topical therapies for impetigo. Pediatr Emerg Care. 2010;26(3):222-227 , quiz 228–231.
18. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol. 2012;29(3):243-248.
19. Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):859-864.
20. National Institute for Health and Care Excellence. Impetigo: antimicrobial prescribing. NICE guideline [NG153]. 2020. Available at: https://www.nice.org.uk/guidance/ng153
21. National Institute for Health and Care Excellence. Impetigo. Clinical Knowledge Summary. 2020. Available at: https://cks.nice.org.uk/impetigo
22. BMJ Group and Pharmaceutical Press. Joint Formulary Committee. British National Formulary (online). Available at: http://www.medicinescomplete.com
23. Davis EC & Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. Clin Aesthet Dermatol 2010;3(7):20–31.
24. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol. 2012;29(3):243-248.
25. Hochedez P, Canestri A, Lecso M, Valin N, Bricaire F, Caumes E. Skin and soft tissue infections in returning travelers. Am J Trop Med Hyg. 2009;80(3):431-434.